Skip to main content
SpringerLink
Log in

Hepatitis B and Hepatitis C Antiviral Agents

  • Chapter
  • First Online:
Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions

Part of the book series: Infectious Disease ((ID))

  • 905 Accesses

Abstract

The hepatitis B virus is currently treated either with a single nucleos(t)ide analog or a finite course of pegylated interferon alfa. These therapies have a low potential for drug interactions but are not devoid of interactions. The treatment of hepatitis C virus has rapidly evolved in recent years. Combinations of agents including inhibitors of the nonstructural (NS) viral protein NS5B polymerase, NS5A, and/or NS3 protease with or without the purine nucleoside analog ribavirin achieve cure rates of at least 90% in most patient populations. The NS3 and NS5A inhibitors participate in a number of important drug interactions, while ribavirin and the NS5B inhibitor, sofosbuvir, have a low potential for interactions. This chapter reviews the pharmacokinetic properties and drug interaction potential of agents used in the treatment of hepatitis B and C viruses, as well as pharmacologic considerations on the use of these therapies in patients with renal or hepatic impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Health Organization (WHO) (2016) Hepatitis B Virus. Updated July 2016. Accessed 17 Aug 2016

    Google Scholar 

  2. World Health Organization (WHO) (2016) Hepatitis C Virus. Updated July 2016. Accessed 17 Aug 2016

    Google Scholar 

  3. Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT et al (2015) Present and future therapies of hepatitis B: from discovery to cure. Hepatology 62(6):1893–1908

    Article  PubMed  PubMed Central  Google Scholar 

  4. Flisiak R, Pogorzelska J, Flisiak-Jackiewicz M, Hepatitis C (2017) Efficacy and safety in real life. Liver Int. 37(Suppl 1):26–32

    Article  CAS  PubMed  Google Scholar 

  5. Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF (2014) Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 26(10):1073–1082

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Asmuth DM, Utay NS, Pollard RB (2016) Peginterferon alpha-2a for the treatment of HIV infection. Expert Opin Investig Drugs. 25(2):249–257

    Article  CAS  PubMed  Google Scholar 

  7. Antonelli G, Scagnolari C, Moschella F, Proietti E (2015) Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 26(2):121–131

    Article  CAS  PubMed  Google Scholar 

  8. Konerman MA, Lok AS (2016) Interferon Treatment for Hepatitis B. Clin Liver Dis. 20(4):645–665

    Article  PubMed  Google Scholar 

  9. Brennan BJ, ZX X, Grippo JF (2013) Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol. 75(2):497–506

    Article  CAS  PubMed  Google Scholar 

  10. Gonzalez SA, Perrillo RP, Hepatitis B (2016) Virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy. Clin Infect Dis. 62(Suppl 4):S306–S313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Noble S, Goa KL (1999) Adefovir dipivoxil. Drugs. 58(3):479–487. discussion 88-9

    Article  CAS  PubMed  Google Scholar 

  12. Rivkin AM (2004) Adefovir dipivoxil in the treatment of chronic hepatitis B. Ann Pharmacother. 38(4):625–633

    Article  CAS  PubMed  Google Scholar 

  13. Baraclude – European medicines agency summary of product characteristics June 26 2011 [Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000623/WC500051984.pdf

  14. Matthews SJ (2006) Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 28(2):184–203

    Article  CAS  PubMed  Google Scholar 

  15. Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D et al (1998) Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol. 46(1):21–27

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kearney BP, Flaherty JF, Shah J (2004) Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 43(9):595–612

    Article  CAS  PubMed  Google Scholar 

  17. Ray AS, Fordyce MW, Hitchcock MJ (2016) Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 125:63–70

    Article  CAS  PubMed  Google Scholar 

  18. Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M et al (2015) Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother. 59(9):5503–5510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ouwerkerk-Mahadevan S B-MM, De Smedt G, et al (2011) The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone. In: 62nd annual meeting of teh American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, 4–8 Nov 2011

    Google Scholar 

  20. Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A et al (2016) Drug-drug interactions between the anti-hepatitis C virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers. Clin Pharmacokinet. 55(8):1003–1014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Fraser IPYW, Reitmann C, et al (2013) Lack of PK interaction between the HCV protease inhibitor MK-5172 and methadone or buprenorphine/naloxone in subjects on opiate maintenance therapy. [abstract O_16_PK]. In: 8th international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 2013

    Google Scholar 

  22. German P, Moorehead L, Pang P, Vimal M, Mathias A (2014) Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. J Clin Pharmacol. 54(11):1290–1298

    Article  CAS  PubMed  Google Scholar 

  23. Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D et al (2014) Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antivir Ther. 19(5):511–519

    Article  CAS  PubMed  Google Scholar 

  24. Ouwerkerk-Mahadevan SSA, Spittaels K, et al (2012) No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone. Poster. In: 63rd annual meeting of teh American Association for the Study of Liver Diseases (AASLD),Boston, MA, 9–13 Nov 2012

    Google Scholar 

  25. Epclusa. sofosbuvir and velpatasvir tablets.

    Google Scholar 

  26. Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A et al (2015) Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 63(1):20–29

    Article  CAS  PubMed  Google Scholar 

  27. Marshall WYW, Caro L, et al (2013) No Pharmacokinetic interaction between the hepatitis c virus non-structural protein 5a inhibitor MK-8742 and ethinyl estradiol and levonorgestrel. [abstract 53]. HEPDART 2013: Frontiers in drug development fo rViral hepatitis, Big Island, 8–12 Dec 2013

    Google Scholar 

  28. Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A (2016) Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet. 55(2):197–208

    Article  CAS  PubMed  Google Scholar 

  29. Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B et al (2015) Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 15(9):1049–1054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zepatier (2016) elbasvir/grazoprevir. prescribing Information. Merck and Co., INC

    Google Scholar 

  31. Caro LTJ, Guo Z et al (2013) Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers. [abstract 477]. Hepatology 58(4 (suppl) AASLD Abstracts):437A

    Google Scholar 

  32. Bifano M CS, Hwang C, et al. The effect of co-administration f the proteon-pump inhibitor omeprazole on the pharmacokinetics of daclatasvir in healthy subjects. In: 48th annual meeting of the European Association for the Study of the Liver, Amsterdan, 24–28 Apr 2013

    Google Scholar 

  33. Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ (2015) An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 35(5):281–289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Mogalian E, German P, Kearney BP, Yang CY, Brainard D, McNally J et al (2015) Use of multiple probes to assess transporter- and Cytochrome P450-mediated drug-drug interaction potential of the Pangenotypic HCV NS5A inhibitor Velpatasvir. Clin Pharmacokinet.

    Google Scholar 

  35. Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T et al (2015) Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 15(5):1313–1322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sovaldi (2015) Sofosbuvir. Prescribing information

    Google Scholar 

  37. Denning J, Cornpropst M, Flach SD, Berrey MM, Symonds WT (2013) Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother. 57(3):1201–1208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kirby BJ, Symonds WT, Kearney BP, Mathias AA (2015) Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 54(7):677–690

    Article  CAS  PubMed  Google Scholar 

  39. Product Information: Sovaldi, sofosbuvir (2015) Gilead Sciences, Inc, Foster City, CA

    Google Scholar 

  40. Desnoyer A, Pospai D, Le MP, Gervais A, Heurgue-Berlot A, Laradi A et al (2016) Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 65(1):40–47

    Article  CAS  PubMed  Google Scholar 

  41. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT et al (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 36(6):807–816

    Article  CAS  PubMed  Google Scholar 

  42. Bhamidimarri KR, Czul F, Peyton A, Levy C, Hernandez M, Jeffers L et al (2015) Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 63(3):763–765

    Article  CAS  PubMed  Google Scholar 

  43. MacBrayne CE, Kiser JJ (2016) Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV. Clin Infect Dis. 63(Suppl 1):S12–S23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Harvoni (2015) ledipasvir and sofosbuvir. Prescribing information. Gilead Sciences.

    Google Scholar 

  45. Liu GTC, Chang C, Rajamani S, Ray AS, Stamm LM, Vick J, Willichinsky M, McHutchinson JG, Brainard DM (2016) Effect of amiodarone and HCV direct-acting antiviral agents on cardiac conduction in nonclinical stuides. In: EASL-The International Liver Congress, Barcelona, 13–17 Apr 2016

    Google Scholar 

  46. Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA et al (2016) Identification of Drug-Drug interactions in vitro: a case study evaluating the effects of sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes. Toxicol Sci. 154(1):174–182

    Article  CAS  PubMed  Google Scholar 

  47. Regan CP, Morissette P, Regan HK, Travis JJ, Gerenser P, Wen J et al (2016) Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys. Hepatology 64(5):1430–1441

    Article  CAS  PubMed  Google Scholar 

  48. Daklinza (2015) daclatasvir (prescribing information)

    Google Scholar 

  49. Garimella T, You X, Wang R, Huang SP, Kandoussi H, Bifano M et al (2016) A review of daclatasvir drug-drug interactions. Adv Ther. 33(11):1867–1884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Eley TYX, Wang R, et al (2014) Daclatasvir: overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs. HIV DART Miami, FL, 9–12 Dec 2014

    Google Scholar 

  51. Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R et al (2013) Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 18(7):931–940

    Article  CAS  PubMed  Google Scholar 

  52. Gandhi YAR, Wang R, et al (2015) Assessment of drug-drug interactions between daclatasvir and darunavir/ritonavir or lopinavir/ritonavir. In: 16th international workshop on clinical pharmacology of HIV and hepatitis therapy, Washington, DC, 26–28 May 2015. Abstract 80

    Google Scholar 

  53. Center for drug evaluation and research: clinical pharmacology and biopharmaceutics review(s) ledipasvir/sofosbuvir (2014)

    Google Scholar 

  54. German P, Fang L, et al (2014) Drug-drug interaction profile of the fixed dose combination tablet ledipasvir/sofosbuvir [abstract 1976]. In: American Association for the study of liver diseases, Boston, MA, 7–11 Nov 2014

    Google Scholar 

  55. Kirby B (2014) Transporters: role in clinical development of HCV compounds. Presentation at the 15th international workshop on clinical pharmacology of HIV and hepatitis therapy,Washington, DC.

    Google Scholar 

  56. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE et al (2016) Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 64(6):1893–1899

    Article  CAS  PubMed  Google Scholar 

  57. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM et al (2016) Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 151(6):1131–1140. e5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Mascolini M (2014) Impact of food and antacids on levels of ledipasvir and sofosbuvir. In: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy, Washington, DC, 19–21 May 2014

    Google Scholar 

  59. German PGK, Pang PS et al (2015) Drug interactions between the anti-HCV regimen ledipasvir/sofosbuvir and ritonavir boosted protease inhibitors plus Emtricitabine/Tenofovir DF. In: 22nd conference on retroviruses and opportunistic infections seattle Washington, DC, 23–26 Feb 2015

    Google Scholar 

  60. German PPP, West S et al (2014) Drug interaction between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. [Abstract 06.]. In: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy, Washington, DC, 19–21 May 2014

    Google Scholar 

  61. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ et al (2015) Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 373(8):705–713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Su F, Green PK, Berry K, Ioannou GN (2017) The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 65(2):426–438

    Article  CAS  PubMed  Google Scholar 

  63. O'Brien TR, Kottilil S, Feld JJ, Morgan TR, Pfeiffer RM (2017) Race or genetic makeup for hepatitis C virus treatment decisions? Hepatology. 65(6):2124–2125

    Article  PubMed  Google Scholar 

  64. Olysio. Simeprevir. Prescribing Information (2015)

    Google Scholar 

  65. Sivi Ouwerkerk-Mahadevan As, Monika Peeters, et al (2013) Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus Ns3/4A protease inhibitor. In: 14th European AIDS conference, Brussels, 16–19 Oct 2013

    Google Scholar 

  66. Sekar VVR, Meyvisch P, et al (2010) Evaluation of metabolic interactions for TMC435 via cytochromie P450 (CYP) enzymes in healthy volunteers [poster]. In: 45th annual meeting of the European Association for the Study of the Liver 9EASL), Vienna, AU, 14–18 Apr 2010

    Google Scholar 

  67. Tischer S, Fontana RJ (2014) Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 60(4):872–884

    Article  CAS  PubMed  Google Scholar 

  68. Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ et al (2015) Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with Genotype 1 or 3 Hepatitis C virus infection: a randomized trial. Ann Intern Med. 163(11):809–817

    Article  PubMed  Google Scholar 

  69. Mathias A (2013) Clinical Pharmacology of DAA’s for HCV: What’s New and What’s in the Pipeline. In: 14th international workshop on clinical pharmacology of HIV therapy, 24 Apr 2013

    Google Scholar 

  70. Mogalian E SL, Osinusi A, et al (2015) Drug-drug interaction studies between Hepatitis C virus antivirals sofosbuvir and Velpatasvir (GS-5816) and HIV antiretoviral therapies. In: 66th annual meeting of the American Association for the Study of Liver Diseases Boston, MA, 13–17 2015

    Google Scholar 

  71. Jacobson IMPF, Firpi-Morell R, et al (2015) Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1—infected patients with Child-Pugh class B cirrhosis (C-SALT Part A). The 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, AU, 22–26 Apr 2015

    Google Scholar 

  72. Yeh WMW, Caro L, et al (2014) Pharmacokinetic interaction of HCV NS5A inhibitor MK-8742 and ketoconazole in healthy subjects {P_27}. In: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy, Washington, DC, 19–21 May 2014

    Google Scholar 

  73. Yeh W (2015) Drug-drug interactions with grazoprevir/elbasvir: practical considerations for the care of HIV/HCV co-infected patients. In: international workshop on clinical pharmacology of HIV & hepatitis therapy, 28 May 2015

    Google Scholar 

  74. TECHNIVIE (2015) Ombitasvir, paritaprevir, and ritonavir tablets. Prescribing information

    Google Scholar 

  75. VIEKIRA PAK (2015) ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets. Prescribing information

    Google Scholar 

  76. Pockros PJRK, Mantry PS, et al (2015) Safety of Ombitasvir/Paritaprevir/Ritonavir plus dasabuvir For treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the Ruby-I study in: European Association for the Study of the Liver, Vienna, AU, 22–26 Apr 2015

    Google Scholar 

  77. Smolders EJ, de Kanter CT, de Knegt RJ, van der Valk M, Drenth JP, Burger DM (2016) Drug-drug interactions between direct-acting antivirals and psychoactive medications. Clin Pharmacokinet. 55(12):1471–1494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Werner JM, Serti E, Chepa-Lotrea X, Stoltzfus J, Ahlenstiel G, Noureddin M et al (2014) Ribavirin improves the IFN-gamma response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology. 60(4):1160–1169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Thomas E, Ghany MG, Liang TJ (2013) The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother. 23(1):1–12

    Article  Google Scholar 

  80. Li L, Koo SH, Limenta LM, Han L, Hashim KB, Quek HH et al (2009) Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. J Clin Pharmacol. 49(6):661–667

    Article  CAS  PubMed  Google Scholar 

  81. Copegus (2015) Ribavirin. Prescribing Information

    Google Scholar 

  82. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P (2001) Mitochondrial toxic effects and ribavirin. Lancet. 357(9270):1803–1804

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO, USA

    Christine E. MacBrayne & Jennifer J. Kiser

Authors
  1. Christine E. MacBrayne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer J. Kiser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer J. Kiser .

Editor information

Editors and Affiliations

  1. College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA

    Manjunath P. Pai

  2. Department of Pharmaceutical Sciences, Skagg School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA

    Jennifer J. Kiser

  3. Division of Pharmacy Practice and Administration, UMKC School of Pharmacy at MSU, Springfield, Missouri, USA

    Paul O. Gubbins

  4. College of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, Illinois, USA

    Keith A. Rodvold

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

MacBrayne, C.E., Kiser, J.J. (2018). Hepatitis B and Hepatitis C Antiviral Agents. In: Pai, M., Kiser, J., Gubbins, P., Rodvold, K. (eds) Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Infectious Disease. Humana Press, Cham. https://doi.org/10.1007/978-3-319-72416-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72416-4_9

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-72415-7

  • Online ISBN: 978-3-319-72416-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation